Plain-English translation of NCT04683315 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Pancreatic Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial tests whether personalizing chemotherapy based on your pancreatic cancer's molecular profile (its unique genetic characteristics) can improve treatment outcomes. Researchers will analyze a small tissue sample taken during a routine procedure to classify your cancer as one of two types. Depending on your cancer's type, you'll receive one of two standard chemotherapy regimens that may work better for your specific subtype.
Pancreatic cancer is aggressive and difficult to treat, and not all patients respond equally to the same chemotherapy. This trial exists to see whether matching patients to the chemotherapy that works best for their particular cancer type — rather than using one-size-fits-all treatment — can improve survival and outcomes.
You likely qualify if…
You likely don't qualify if…
You will have a tissue sample collected from your pancreas during an endoscopic ultrasound procedure (a routine test your doctor may already be planning). This sample will be analyzed to determine your cancer's molecular type. Based on the results, you'll receive two months of one of two standard chemotherapy regimens — either gemcitabine/nab-paclitaxel or mFOLFIRINOX — whichever is tailored to your cancer type. You'll have regular clinic visits for treatment administration and monitoring during this period.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
United States